Company,Event_Date,Stock_Date,Classification,Title,Significance_Score,pre_event_CAR,pre_event_AAR,pre_event_days,event_day_CAR,event_day_AAR,event_day_days,post_event_CAR,post_event_AAR,post_event_days,full_window_CAR,full_window_AAR,full_window_days
Biocon,2017-05-10,2017-05-10,Bad,Biocon downplays FDA Form 483 for Bangalore plant - Fierce Pharma,0.4598251973620654,-0.008266895292672112,-0.0027556317642240375,3,-0.03186974728534122,-0.03186974728534122,1,-0.009504752952793127,-0.003168250984264376,3,-0.04964139553080646,-0.007091627932972351,7
Biocon,2017-10-10,2017-10-09,Bad,Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL - Fierce Pharma,0.5070454545454546,0.005992809215621,0.001997603071873667,3,-0.018540268663164702,-0.018540268663164702,1,0.004710321675111696,0.001570107225037232,3,-0.007837137772432006,-0.0011195911103474294,7
Biocon,2018-02-21,2018-02-21,Bad,Plant where Biocon and Mylan will produce their Lantus copy spanked with FDA Form 483 - Fierce Pharma,0.4271385663525883,-0.022203943842907928,-0.007401314614302643,3,0.00612309174137823,0.00612309174137823,1,-0.008728444229888152,-0.004364222114944076,2,-0.024809296331417853,-0.004134882721902975,6
Biocon,2019-12-03,2019-12-03,Good,Biocon gets FDA approval to produce pegfilgrastim in India - Fierce Pharma,0.5324652289895009,0.04502884733764417,0.015009615779214724,3,0.005205016894123269,0.005205016894123269,1,0.007025614464708304,0.0023418714882361014,3,0.05725947869647575,0.008179925528067964,7
Biocon,2020-06-11,2020-06-11,Good,Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) - PR Newswire,0.5412774935554061,-0.009793351074301751,-0.003264450358100584,3,0.013661239053035422,0.013661239053035422,1,-0.006572860748678577,-0.0021909535828928592,3,-0.0027049727699449064,-0.0003864246814207009,7
Biocon,2021-06-11,2021-06-11,Good,FDA Approves Biocon's Semglee as Biosimilar to Lantus,0.5102688333040302,0.04852745951235526,0.012131864878088814,4,-0.011366877143272324,-0.011366877143272324,1,-0.012670834577624175,-0.004223611525874725,3,0.024489747791458766,0.003061218473932344,8
Biocon,2021-07-29,2021-07-29,Good,FDA Approves Biocon's Semglee as First Interchangeable Biosimilar,0.5122176094143278,-0.01286902675218189,-0.00428967558406063,3,-0.00164677917985875,-0.00164677917985875,1,-0.0026165416354627397,-0.0008721805451542466,3,-0.01713234756750338,-0.0024474782239290544,7
Biocon,2023-02-13,2023-02-13,Bad,Biocon's proposed Avastin biosim hit with FDA rejection after failed plant inspection - Fierce Pharma,0.4550700366906426,0.00635771577397122,0.0021192385913237403,3,-0.017997546912825874,-0.017997546912825874,1,-0.005698013087516114,-0.0014245032718790285,4,-0.017337844226370767,-0.002167230528296346,8
Biocon,2023-02-14,2023-02-14,Bad,"FDA Issues CRL for Biocon Biologics, Viatris Avastin Biosimilar - Center for Biosimilars",0.4609284734368329,-0.022547726228148712,-0.0075159087427162374,3,-0.006804690486041089,-0.006804690486041089,1,0.0011066773985249773,0.00036889246617499244,3,-0.028245739315664823,-0.004035105616523546,7
Biocon,2023-10-09,2023-10-09,Bad,FDA hits Biocon's insulin copycat with a CRL as plant awaits pre-approval inspection - Fierce Pharma,0.4806429728497933,-0.01614950154439768,-0.005383167181465893,3,-0.013900169066041352,-0.013900169066041352,1,-0.02115730029958182,-0.005289325074895455,4,-0.051206970910020855,-0.006400871363752607,8
Biocon,2024-05-21,2024-05-21,Good,Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market - PR Newswire,0.5389115437152878,-0.011122227923927617,-0.005561113961963808,2,0.0028348816577878485,0.0028348816577878485,1,0.03190931516950572,0.01063643838983524,3,0.02362196890336595,0.003936994817227659,6
Biocon,2024-05-21,2024-05-21,Good,"FDA Approves Biocon Biologics’ Yesafili, an Eylea Biosimilar, for the Treatment of Multiple Ophthalmic Conditions - Pharmaceutical Executive",0.5239115437152878,-0.011122227923927617,-0.005561113961963808,2,0.0028348816577878485,0.0028348816577878485,1,0.03190931516950572,0.01063643838983524,3,0.02362196890336595,0.003936994817227659,6
Biocon,2024-08-30,2024-08-30,Good,Biocon arm Biocon Pharma receives US FDA approval for Daptomycin injection - CNBC TV18,0.5443678105900815,0.0034090324755598343,0.0008522581188899586,4,-0.0012266481577306223,-0.0012266481577306223,1,0.04702405676230513,0.015674685587435042,3,0.04920644108013435,0.006150805135016793,8
Biocon,2024-09-01,2024-09-02,Good,Biocon Pharma receives USFDA approval for daptomycin - Indian Pharma Post,0.5470454545454545,0.003205708990806702,0.001068569663602234,3,0.015802185888773117,0.015802185888773117,1,0.0269229384357375,0.006730734608934375,4,0.04593083331531732,0.005741354164414665,8
Biocon,2024-12-01,2024-12-02,Good,Biocon Biologics secures US FDA approval to commercialise YESINTEK - BusinessLine,0.5470454545454545,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-01,2024-12-02,Good,"USFDA approves Biocon Biologics' biosimilar for Crohn's disease, psoriasis - Business Standard",0.5320454545454545,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-01,2024-12-02,Good,US FDA approves Biocon Biologics' YESINTEK for autoimmune diseases - CNBC TV18,0.4970454545454545,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,Biocon Shares Rally 4% as Subsidiary Receives USFDA Approval - Equitypandit,0.565565996155653,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,FDA approves Biocon biosimilar Yesintek - The Pharma Letter,0.5505659961556529,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,"FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek - Center for Biosimilars",0.5505659961556529,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,"U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab) - PR Newswire",0.5505659961556529,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,Biocon shares rise 4% after US FDA approves Yesintek - Moneycontrol,0.515565996155653,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2024-12-02,2024-12-02,Good,"USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis,... - Medical Dialogues",0.515565996155653,0.021751736402250203,0.0072505788007500675,3,0.009698063048264007,0.009698063048264007,1,0.00038872666694340224,9.718166673585056e-05,4,0.03183852611745761,0.0039798157646822015,8
Biocon,2025-01-07,2025-01-06,Good,"Biocon stock zooms over 8% on Psoriasis drug approval from Japan, Jefferies rating upgrade - Mint",0.5920454545454545,0.02024615564110748,0.006748718547035827,3,-0.020564546877219897,-0.020564546877219897,1,-0.030143660686365106,-0.010047886895455035,3,-0.030462051922477522,-0.004351721703211075,7
Biocon,2025-01-13,2025-01-13,Good,Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDA - The Economic Times,0.526174830237611,-0.030143660686365106,-0.010047886895455035,3,0.018581098465042148,0.018581098465042148,1,0.05185660771451777,0.012964151928629443,4,0.04029404549319481,0.0050367556866493515,8
Biocon,2025-01-13,2025-01-13,Good,Biocon Shares Gain 4% as Malaysia Unit Gets Clearance from USFDA - Equitypandit,0.526174830237611,-0.030143660686365106,-0.010047886895455035,3,0.018581098465042148,0.018581098465042148,1,0.05185660771451777,0.012964151928629443,4,0.04029404549319481,0.0050367556866493515,8
Biocon,2025-03-24,2025-03-24,Good,Biocon subsidiary secures FDA approval for critical blood pressure medication - BusinessLine,0.5501797094790878,-0.004943707394955447,-0.001647902464985149,3,0.007662481391082746,0.007662481391082746,1,0.008616482606921593,0.002154120651730398,4,0.011335256603048892,0.0014169070753811113,8
Biocon,2025-03-24,2025-03-24,Good,Biocon rises after subsidiary gets US FDA approval for Norepinephrine Bitartrate Injection - Business Standard,0.5501797094790878,-0.004943707394955447,-0.001647902464985149,3,0.007662481391082746,0.007662481391082746,1,0.008616482606921593,0.002154120651730398,4,0.011335256603048892,0.0014169070753811113,8
Biocon,2025-03-24,2025-03-24,Good,Biocon Pharma gets USFDA approval for BP-raising injection in adults with acute hypotension - Medical Dialogues,0.5501797094790878,-0.004943707394955447,-0.001647902464985149,3,0.007662481391082746,0.007662481391082746,1,0.008616482606921593,0.002154120651730398,4,0.011335256603048892,0.0014169070753811113,8
Biocon,2025-04-10,2025-04-09,Good,"Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire",0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon Biologics receives U.S. FDA approval for Jobevne - The Hindu,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon Pharma Gains US FDA Approval for Everolimus Tablets - TipRanks,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon arm announces U.S. FDA approval for Jobevne - Moneycontrol,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon share price rises 4% on US FDA approval for cancer drug - TradingView,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon Biologics receives USFDA approval for Jobevne (Biosimilar Bevacizumab) - Business Standard,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,"Biocon Biologics gets US FDA approval for Biosimilar Bevacizumab, expanding oncology portfolio - BioSpectrum India",0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,"Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE - Express Pharma",0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon Subsidiary Secures USFDA Approval - Equitypandit,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Biocon Biologics bags US FDA approval for Jobevne to treat cancer - IndiaMedToday,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,Pharma stock in focus: Biocon arm announces USFDA approval for Jobevne - Business Today,0.5470454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,FDA Approves Biocon Biologics' Bevacizumab Biosimilar - Center for Biosimilars,0.5320454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,FDA Approves Biocon’s Avastin Biosimilar - Managed Healthcare Executive,0.5320454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-10,2025-04-09,Good,"Biocon Says U.S. FDA Approves Biocon Biologics's Bevacizumab Biosimilar, Jobevne - MarketScreener",0.5320454545454545,-0.02177458850739072,-0.00725819616913024,3,-0.024842162594524042,-0.024842162594524042,1,0.012420597817288749,0.012420597817288749,1,-0.03419615328462602,-0.006839230656925203,5
Biocon,2025-04-11,2025-04-11,Good,Biocon Biologics secures FDA approval for Avastin biosimilar Jobevne - World Pharmaceutical Frontiers,0.5722022231425704,-0.031106201087427055,-0.010368733695809018,3,0.012420597817288749,0.012420597817288749,1,0.012970239568658065,0.006485119784329032,2,-0.005715363701480241,-0.0009525606169133735,6
Biocon,2025-04-11,2025-04-11,Good,Biocon Biologics secures FDA approval for cancer drug Jobevne - BusinessLine,0.5722022231425704,-0.031106201087427055,-0.010368733695809018,3,0.012420597817288749,0.012420597817288749,1,0.012970239568658065,0.006485119784329032,2,-0.005715363701480241,-0.0009525606169133735,6
Biocon,2025-04-11,2025-04-11,Good,Biocon arm secures USFDA approval for Everolimus Tablets for prophylaxis of organ rejection in adult... - Medical Dialogues,0.5722022231425704,-0.031106201087427055,-0.010368733695809018,3,0.012420597817288749,0.012420597817288749,1,0.012970239568658065,0.006485119784329032,2,-0.005715363701480241,-0.0009525606169133735,6
Biocon,2025-04-11,2025-04-11,Good,"Biocon Shares in Focus, Strengthens US Oncology Footprint with Biosimilar Approval - Groww",0.5722022231425704,-0.031106201087427055,-0.010368733695809018,3,0.012420597817288749,0.012420597817288749,1,0.012970239568658065,0.006485119784329032,2,-0.005715363701480241,-0.0009525606169133735,6
Biocon,2025-04-11,2025-04-11,Good,FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer - Pharmaceutical Technology,0.5572022231425704,-0.031106201087427055,-0.010368733695809018,3,0.012420597817288749,0.012420597817288749,1,0.012970239568658065,0.006485119784329032,2,-0.005715363701480241,-0.0009525606169133735,6
Dr. Reddy's,2015-11-25,2015-11-24,Bad,Premium: US FDA Warning Letter to Dr. Reddy’s – Here is an Additional Update - Capitalmind,0.4840909090909091,0.02124714859343803,0.007082382864479343,3,0.002894296358584238,0.002894296358584238,1,-0.00504486368498089,-0.00504486368498089,1,0.019096581267041376,0.0038193162534082754,5
Dr. Reddy's,2015-11-26,2015-11-27,Bad,Warning letter: USFDA flags ‘serious violations’ at Dr Reddy’s - The Indian Express,0.4670454545454546,0.015734166337998203,0.007867083168999102,2,-0.00504486368498089,-0.00504486368498089,1,0.03223235964430985,0.010744119881436616,3,0.04292166229732716,0.007153610382887861,6
Dr. Reddy's,2016-02-01,2016-02-01,Good,Dr. Reddy's Laboratories Ltd. Receives FDA Approval for ZEMBRACE™SymTouch™ (sumatriptan succinate) Injection for the Acute Treatment of Migraines in Adults - Fierce Pharma,0.5470454545454545,0.02088773948298066,0.006962579827660221,3,-0.009386172396156927,-0.009386172396156927,1,0.029636500349015583,0.007409125087253896,4,0.041138067435839316,0.0051422584294799146,8
Dr. Reddy's,2017-01-24,2017-01-24,Good,"Mezzion sues Dr. Reddy's for fraud, citing plant problems that cost it a drug approval - Fierce Pharma",0.5470454545454545,0.0018586086714819684,0.0006195362238273228,3,0.007593907642952475,0.007593907642952475,1,-0.0005615834314886786,-0.0002807917157443393,2,0.008890932882945766,0.0014818221471576277,6
Dr. Reddy's,2017-05-01,2017-05-02,Bad,FDA cites third Dr. Reddy's plant this year - Fierce Pharma,0.4270454545454545,0.005218585038526315,0.0026092925192631577,2,0.005900397151085663,0.005900397151085663,1,0.02301886080524901,0.00767295360174967,3,0.03413784299486099,0.0056896404991434975,6
Dr. Reddy's,2017-10-20,2017-10-19,Bad,"Dr. Reddy's, fighting to recover from FDA warning letter, recalls 500K heartburn tablets - Fierce Pharma",0.5061363636363636,-0.003175283807353692,-0.001058427935784564,3,0.0046739253123584965,0.0046739253123584965,1,0.007988951676017632,0.003994475838008816,2,0.009487593181022436,0.001581265530170406,6
Dr. Reddy's,2017-10-27,2017-10-27,Bad,"FiercePharmaAsia—Dr. Reddy’s drug recall, China’s Ebola vaccine, Bharat Biotech’s typhoid vaccine - Fierce Pharma",0.4720454545454545,0.0038707817455416373,0.0009676954363854093,4,0.011064205632996964,0.011064205632996964,1,-0.012739981870364354,-0.0042466606234547845,3,0.0021950055081742456,0.00027437568852178114,8
Dr. Reddy's,2018-05-15,2018-05-15,Good,DRL Announces FDA Approval for Generic Suboxone,0.5395454545454546,0.002024955283298876,0.0006749850944329586,3,-0.0007880037932382934,-0.0007880037932382934,1,-0.009906795853054153,-0.0033022652843513844,3,-0.00866984436299357,-0.0012385491947133672,7
Dr. Reddy's,2018-06-15,2018-06-15,Good,Indivior shares dive after Dr Reddy's gets FDA approval for generic - Yahoo,0.5470454545454545,0.019525931727031754,0.006508643909010584,3,0.012300122326346696,0.012300122326346696,1,0.010550563905871089,0.003516854635290363,3,0.04237661795924953,0.006053802565607076,7
Dr. Reddy's,2018-06-15,2018-06-15,Good,Dr Reddy’s gets US FDA approval to launch Suboxone generic | Company Business News - Mint,0.5470454545454545,0.019525931727031754,0.006508643909010584,3,0.012300122326346696,0.012300122326346696,1,0.010550563905871089,0.003516854635290363,3,0.04237661795924953,0.006053802565607076,7
Dr. Reddy's,2018-06-18,2018-06-18,Bad,Dr. Reddy's forced to stop Suboxone generic rollout amid Indivior patent dispute - Fierce Pharma,0.4520454545454546,0.02729976852901918,0.009099922843006394,3,0.013205538755838842,0.013205538755838842,1,-0.02150136663296872,-0.00537534165824218,4,0.0190039406518893,0.002375492581486163,8
Dr. Reddy's,2019-02-14,2019-02-14,Bad,Dr. Reddy's Receives FDA Warning Letter for Srikakulam Facility,0.4936363636363636,0.004210287412820491,0.004210287412820491,1,0.0018605204026311958,0.0018605204026311958,1,0.0018933986752249256,0.0006311328917416419,3,0.007964206490676614,0.0015928412981353226,5
Dr. Reddy's,2019-07-23,2019-07-23,Good,Dr Reddy's launches insomnia treatment tablets in US after FDA approval - Business Standard,0.5470454545454545,-0.012063389420015,-0.004021129806671666,3,-0.0019372225208772569,-0.0019372225208772569,1,0.021109600647345243,0.007036533549115081,3,0.0071089887064529865,0.0010155698152075694,7
Dr. Reddy's,2020-05-12,2020-05-12,Bad,Dr. Reddy's Laboratories recalls bottles of generic Nexium on quality concerns - Fierce Pharma,0.4720454545454545,-0.0017564732386770934,-0.0005854910795590312,3,-0.007384145547138185,-0.007384145547138185,1,0.019928759284974,0.006642919761658,3,0.010788140499158723,0.0015411629284512462,7
Dr. Reddy's,2020-08-26,2020-08-26,Good,Dr. Reddy's Receives FDA Approval for Generic Revlimid,0.5395454545454546,-0.0020268559283535045,-0.0006756186427845015,3,-0.0026639741495773804,-0.0026639741495773804,1,-0.01935378174231064,-0.0064512605807702135,3,-0.024044611820241524,-0.003434944545748789,7
Dr. Reddy's,2021-12-03,2021-12-03,Bad,FDA Inspection at Dr. Reddy's Hyderabad Facility Concludes,0.4565909090909091,-0.014644848353360298,-0.0036612120883400745,4,-0.0023131706485445807,-0.0023131706485445807,1,-0.019386172850926787,-0.006462057616975596,3,-0.036344191852831664,-0.004543023981603959,8
Dr. Reddy's,2022-02-09,2022-02-09,Good,"Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market - NDTV",0.5470454545454545,-0.02045948475397759,-0.006819828251325863,3,0.005857800656981933,0.005857800656981933,1,-0.00491373036993536,-0.0016379101233117866,3,-0.019515414466931016,-0.0027879163524187167,7
Dr. Reddy's,2022-09-08,2022-09-08,Good,"Dr. Reddy’s Launches, Cipla Receives Approval for Generic Revlimid - Managed Healthcare Executive",0.5470454545454545,-0.005550084964941458,-0.0018500283216471526,3,0.005985726545865793,0.005985726545865793,1,-0.0034692676249982925,-0.0011564225416660974,3,-0.0030336260440739574,-0.00043337514915342247,7
Dr. Reddy's,2022-09-18,2022-09-19,Good,Dr Reddy Gets FDA Approval for Generic EpiPen,0.5395454545454546,-0.005264545197051998,-0.0017548483990173327,3,0.0029173924360833456,0.0029173924360833456,1,-0.001624782151752542,-0.0004061955379381355,4,-0.0039719349127211945,-0.0004964918640901492,8
Dr. Reddy's,2023-03-07,2023-03-06,Good,DRREDDY Receives FDA Clearance for Manufacturing Facility,0.5195454545454545,0.02178203029944966,0.00726067676648322,3,-3.487970681204512e-06,-3.487970681204512e-06,1,0.0019704362230682604,0.0006568120743560868,3,0.023748978551836712,0.003392711221690959,7
Dr. Reddy's,2023-11-30,2023-11-30,Bad,Dr. Reddy's scolded for maintenance shortfalls in new FDA Form 483 filing - Fierce Pharma,0.4270454545454545,0.005323617974348291,0.0026618089871741457,2,0.0004575356477594765,0.0004575356477594765,1,-0.01011064700155745,-0.0033702156671858168,3,-0.004329493379449683,-0.0007215822299082805,6
Dr. Reddy's,2024-02-12,2024-02-12,Bad,Dr Reddy's Laboratories R&D facility gets VAI status in USFDA inspection - Business Standard,0.4470454545454546,0.013623614279487167,0.004541204759829056,3,0.027990184521224905,0.027990184521224905,1,-0.01874942714636914,-0.004687356786592285,4,0.022864371654342932,0.0028580464567928665,8
Dr. Reddy's,2024-06-25,2024-06-25,Bad,FDA slams Dr. Reddy's plants in India with a pair of Form 483s - Fierce Pharma,0.4270454545454545,0.004621009599642982,0.0015403365332143273,3,0.0035654854774142698,0.0035654854774142698,1,0.021872451938241028,0.0072908173127470095,3,0.03005894701529828,0.0042941352878997545,7
Dr. Reddy's,2024-08-12,2024-08-12,Good,Dr Reddy's Labs gets US FDA clearance: Visakhapatnam facilities classified as VAI - Express Pharma,0.5270454545454546,0.013624892667726967,0.004541630889242323,3,-0.012289287686442583,-0.012289287686442583,1,-0.012575371159831619,-0.0041917903866105395,3,-0.011239766178547234,-0.0016056808826496048,7
Dr. Reddy's,2025-02-10,2025-02-10,Bad,Dr Reddy's Gets FDA Nod For Generic Revlimid - BW Healthcare,0.4520454545454546,-0.0006397169814141204,-0.00021323899380470678,3,0.0014267263206571047,0.0014267263206571047,1,0.01917699186719443,0.004794247966798608,4,0.019964001206437418,0.0024955001508046772,8
Sun Pharma,2016-03-15,2016-03-15,Good,Sun Pharma Receives FDA Approval for Generic Advair Diskus,0.551059089316553,-0.0005403378108436146,-0.0001801126036145382,3,0.0028988050025313336,0.0028988050025313336,1,-0.01707182865502547,-0.005690609551675156,3,-0.014713361463337748,-0.002101908780476821,7
Sun Pharma,2017-05-25,2017-05-25,Good,Problems at Sun Pharma plant trip up drug approval - BioPharma Dive,0.5558065785306446,0.0025819001304886423,0.0008606333768295475,3,-0.01681271408434773,-0.01681271408434773,1,-0.026637204071846658,-0.013318602035923329,2,-0.04086801802570575,-0.006811336337617625,6
Sun Pharma,2017-10-17,2017-10-17,Good,India’s Sun Pharma says its Dadra manufacturing plant gets FDA clearance - Fierce Pharma,0.5136874645158336,0.012915812626198397,0.0043052708753994655,3,-0.008419552718689854,-0.008419552718689854,1,-0.003415372065452383,-0.0017076860327261915,2,0.00108088784205616,0.00018014797367602668,6
Sun Pharma,2017-11-08,2017-11-08,Bad,FDA Issues Warning Letter to Sun Pharma Halol Facility,0.4847903737278123,-0.030559797282584285,-0.010186599094194762,3,0.01698638477933226,0.01698638477933226,1,0.01691671606287615,0.00563890535429205,3,0.0033433035596241237,0.0004776147942320177,7
Sun Pharma,2018-03-21,2018-03-21,Good,Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis - PR Newswire,0.5420702332299816,0.0091377026987585,0.0030459008995861667,3,-0.005403314922644552,-0.005403314922644552,1,0.007952858522535106,0.0026509528408450353,3,0.011687246298649055,0.0016696066140927221,7
Sun Pharma,2018-08-16,2018-08-16,Good,Sun Pharma receives FDA approval for dry eye drug - BioPharma Dive,0.567738191269955,0.0021222317851368883,0.0021222317851368883,1,0.0013937673882035845,0.0013937673882035845,1,-0.0027941829194213074,-0.0009313943064737691,3,0.0007218162539191653,0.00014436325078383307,5
Sun Pharma,2018-09-14,2018-09-14,Good,Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension - Business Wire,0.560388403384169,0.012516474870857667,0.004172158290285889,3,-0.006159184972192595,-0.006159184972192595,1,-0.021102661074014595,-0.007034220358004865,3,-0.014745371175349522,-0.002106481596478503,7
Sun Pharma,2018-09-14,2018-09-14,Good,Sun Pharma’s Xelprost Wins FDA Approval - PharmaLive,0.560388403384169,0.012516474870857667,0.004172158290285889,3,-0.006159184972192595,-0.006159184972192595,1,-0.021102661074014595,-0.007034220358004865,3,-0.014745371175349522,-0.002106481596478503,7
Sun Pharma,2019-05-22,2019-05-22,Good,Sun Pharma Gets FDA Approval for Odefsey Generic,0.5607934695485662,-0.007998649863649602,-0.002666216621216534,3,0.020485866739182818,0.020485866739182818,1,-0.03330522813660389,-0.011101742712201296,3,-0.02081801126107067,-0.0029740016087243812,7
Sun Pharma,2020-08-10,2020-08-10,Bad,"Sun Pharma, Lupin launch U.S. recalls of blood pressure, epilepsy meds - Fierce Pharma",0.4978856332403505,0.013280714179389905,0.004426904726463302,3,-2.43179130088797e-05,-2.43179130088797e-05,1,0.013552172268184663,0.003388043067046166,4,0.026808568534565688,0.003351071066820711,8
Sun Pharma,2021-12-16,2021-12-16,Good,Sun Pharma Wins U.S. FDA Approval For Anti-Fungal Injection — Analyst Take - NDTV Profit,0.548533405928448,0.006924528826575262,0.0023081762755250874,3,0.0031880419426412315,0.0031880419426412315,1,0.02146971723374924,0.007156572411249747,3,0.03158228800296573,0.004511755428995104,7
Sun Pharma,2023-02-14,2023-02-14,Bad,Sun Pharma recalls generic for high blood pressure after failed FDA lab test - Fierce Pharma,0.4670923299870235,0.007238109679988098,0.0024127032266626994,3,-0.0024640970650538947,-0.0024640970650538947,1,-0.00928484716472635,-0.0030949490549087833,3,-0.004510834549792144,-0.000644404935684592,7
Sun Pharma,2023-08-21,2023-08-21,Bad,Sun Pharma Seeks Recall Of Unapproved Phenobarbital Following Approval Of Its Product - insights.citeline.com,0.4646887627091707,-0.008830622201267228,-0.002943540733755743,3,-0.002929085436148617,-0.002929085436148617,1,-0.004790883389964924,-0.001197720847491231,4,-0.016550591027380768,-0.002068823878422596,8
Sun Pharma,2023-10-06,2023-10-06,Good,US FDA approves NDA for Sun Pharma's alopecia drug Deuruxolitinib - Business Standard,0.4908383033607583,0.0007462083502777863,0.0002487361167592621,3,0.0018460065013812263,0.0018460065013812263,1,0.00035352508579592455,0.00011784169526530819,3,0.0029457399374549368,0.000420819991064991,7
Sun Pharma,2024-07-03,2024-07-03,Bad,Warning letter: USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility - The Economic Times,0.4598404290175036,-0.016632456123223543,-0.0055441520410745146,3,-0.004240469480687402,-0.004240469480687402,1,-0.0035459929900201583,-0.0011819976633400528,3,-0.024418918593931107,-0.003488416941990158,7
Sun Pharma,2024-07-26,2024-07-26,Good,Sun Pharma receives US FDA approval for drug to treat alopecia areata - Business Standard,0.5669476685207869,-0.0030814567534562954,-0.0007703641883640738,4,0.010064184400847696,0.010064184400847696,1,0.014068163795899518,0.004689387931966506,3,0.02105089144329092,0.002631361430411365,8
Sun Pharma,2024-07-26,2024-07-26,Good,Sun Pharma gets USFDA approval for Alopecia treatment drug - CNBC TV18,0.5669476685207869,-0.0030814567534562954,-0.0007703641883640738,4,0.010064184400847696,0.010064184400847696,1,0.014068163795899518,0.004689387931966506,3,0.02105089144329092,0.002631361430411365,8
Sun Pharma,2024-07-26,2024-07-26,Good,Sun Pharma receives USFDA approval for LEQSELVI (deuruxolitinib) 8 mg tablets - Business Standard,0.5669476685207869,-0.0030814567534562954,-0.0007703641883640738,4,0.010064184400847696,0.010064184400847696,1,0.014068163795899518,0.004689387931966506,3,0.02105089144329092,0.002631361430411365,8
Sun Pharma,2024-07-26,2024-07-26,Good,FDA approves Sun Pharma’s JAK inhibitor for alopecia - Pharmaceutical Technology,0.5169476685207869,-0.0030814567534562954,-0.0007703641883640738,4,0.010064184400847696,0.010064184400847696,1,0.014068163795899518,0.004689387931966506,3,0.02105089144329092,0.002631361430411365,8
Sun Pharma,2024-07-28,2024-07-29,Good,"FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer - MedCity News",0.5470454545454545,0.008854834670554037,0.0029516115568513457,3,0.011705215267339215,0.011705215267339215,1,0.0011246867994749808,0.0002811716998687452,4,0.021684736737368236,0.002710592092171029,8
Sun Pharma,2024-07-29,2024-07-29,Good,FDA approves Sun Pharma’s alopecia drug Leqselvi | Pharmaceutical | The Pharmaletter - The Pharma Letter,0.4883455103916609,0.008854834670554037,0.0029516115568513457,3,0.011705215267339215,0.011705215267339215,1,0.0011246867994749808,0.0002811716998687452,4,0.021684736737368236,0.002710592092171029,8
Sun Pharma,2024-07-30,2024-07-30,Good,FDA approves Sun Pharma’s oral JAK inhibitor Leqselvi to treat severe alopecia areata - PMLiVE,0.4971216275453032,0.023282125035402716,0.007760708345134239,3,-0.0038980872484085678,-0.0038980872484085678,1,0.0050227740478835485,0.0016742580159611828,3,0.0244068118348777,0.0034866874049825284,7
Sun Pharma,2024-09-06,2024-09-06,Good,Sun Pharma-Moebius Medical anti-osteoarthritis pain drug gets USFDA fast track status - The Economic Times,0.4833265443055193,-0.005547261251182672,-0.001386815312795668,4,0.009353027978234769,0.009353027978234769,1,-0.0018275511493877515,-0.0006091837164625838,3,0.0019782155776643454,0.00024727694720804306,8
Sun Pharma,2025-05-16,2025-05-16,Good,Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis - PR Newswire,0.5356314019693516,-0.036899447493733,-0.00922486187343325,4,-0.0013850292156034711,-0.0013850292156034711,1,-0.0016931905141132088,-0.0005643968380377363,3,-0.03997766722344967,-0.0049972084029312105,8
Sun Pharma,2025-05-16,2025-05-16,Good,Sun Pharma gets USFDA approval for new device to treat skin disease - Business Standard,0.5356314019693516,-0.036899447493733,-0.00922486187343325,4,-0.0013850292156034711,-0.0013850292156034711,1,-0.0016931905141132088,-0.0005643968380377363,3,-0.03997766722344967,-0.0049972084029312105,8
Sun Pharma,2025-05-16,2025-05-16,Good,Sun Pharma Announces FDA Approval Of Next Generation BLU-U Blue Light Photodynamic Therapy Illuminator - MarketScreener,0.5356314019693516,-0.036899447493733,-0.00922486187343325,4,-0.0013850292156034711,-0.0013850292156034711,1,-0.0016931905141132088,-0.0005643968380377363,3,-0.03997766722344967,-0.0049972084029312105,8
Sun Pharma,2025-05-16,2025-05-16,Good,FDA Approves Sun Pharma's New LED BLU-U Device for AK - Dermatology Times,0.4856314019693515,-0.036899447493733,-0.00922486187343325,4,-0.0013850292156034711,-0.0013850292156034711,1,-0.0016931905141132088,-0.0005643968380377363,3,-0.03997766722344967,-0.0049972084029312105,8
Sun Pharma,2025-05-18,2025-05-19,Good,Sun Pharma gets FDA approval for new device to treat skin disease - Indian Pharma Post,0.5470454545454545,-0.005563837507618761,-0.0018546125025395868,3,-0.0008941218090984956,-0.0008941218090984956,1,-0.010029578461523636,-0.002507394615380909,4,-0.016487537778240892,-0.0020609422222801115,8
Sun Pharma,2025-05-19,2025-05-19,Good,Sun Pharma rises after USFDA approves next-gen Blue Light PDT device for actinic keratosis - Business Standard,0.4852964409089657,-0.005563837507618761,-0.0018546125025395868,3,-0.0008941218090984956,-0.0008941218090984956,1,-0.010029578461523636,-0.002507394615380909,4,-0.016487537778240892,-0.0020609422222801115,8
